MTMiquel Perez Torres

Miquel Perez Torres

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Miquel Perez Torres has a total of 3 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Una mirada crítica en l’alfabetització en Inteligencia Artificial per l’educació STEM

    by Miquel Pérez Torres, Francisco José Castillo Hernández

    L’accessibilitat a tecnologies basades en intel·ligència artificial (IA), especialment dels models de llenguatge extensos (LLMs), ha generat un canvi disruptiu en l’ensenyament de les STEM (Ciència, Tecnologia, Enginyeria i Matemàtiques). Aquest article presenta una mirada crítica sobre la integració d’aquestes eines a l’aula, alertant sobre els riscos d’incorporar-les a l’aula com a recursos pedagògics neutres. A través de quatre exemples, es plantegen dilemes ètics i pedagògics que posen en qüestió l’impacte d’aquestes eines a l’educació STEM. L’article defensa la necessitat d’una alfabetització crítica en IA per a docents i alumnes, ancorada en valors com l’equitat, la responsabilitat i la transparència. Finalment, es proposa repensar les tecnologies IA des d’un enfocament socioconstructivista, alineat amb els canvis en les pràctiques científiques i els reptes socials contemporanis.

  • Open Access

    Effective immunosuppression with dexamethasone phosphate in the Galleria mellonella larva infection model resulting in enhanced virulence of Escherichia coli and Klebsiella pneumoniae

    by Miquel Perez Torres, Frances Entwistle, Peter J. Coote

    The aim was to evaluate whether immunosuppression with dexamethasone 21-phosphate could be applied to the Galleria mellonella in vivo infection model. Characterised clinical isolates of Escherichia coli or Klebsiella pneumoniae were employed, and G. mellonella larvae were infected with increasing doses of each strain to investigate virulence in vivo. Virulence was then compared with larvae exposed to increasing doses of dexamethasone 21-phosphate. The effect of dexamethasone 21-phosphate on larval haemocyte phagocytosis in vitro was determined via fluorescence microscopy and a burden assay measured the growth of infecting bacteria inside the larvae. Finally, the effect of dexamethasone 21-phosphate treatment on the efficacy of ceftazidime after infection was also noted. The pathogenicity of K. pneumoniae or E. coli in G. mellonella larvae was dependent on high inoculum numbers such that virulence could not be attributed specifically to infection by live bacteria but also to factors associated with dead cells. Thus, for these strains, G. mellonella larvae do not constitute an ideal infection model. Treatment of larvae with dexamethasone 21-phosphate enhanced the lethality induced by infection with E. coli or K. pneumoniae in a dose- and inoculum size-dependent manner. This correlated with proliferation of bacteria in the larvae that could be attributed to dexamethasone inhibiting haemocyte phagocytosis and acting as an immunosuppressant. Notably, prior exposure to dexamethasone 21-phosphate reduced the efficacy of ceftazidime in vivo. In conclusion, demonstration of an effective immunosuppressant regimen can improve the specificity and broaden the applications of the G. mellonella model to address key questions regarding infection.